BioCentury | Mar 7, 2016
Clinical News

CDX-301: Interim Phase II data

...with hematologic malignancies in an open-label, U.S. Phase II trial showed that 75 ug/kg/day subcutaneous CDX-301...
...graft contained increases in naive lymphocytes and plasmacytoid dendritic cells compared to administration of G-CSF. CDX-301...
...to evaluate CDX-301 in combination with Mozobil. Celldex has exclusive rights to develop and commercialize CDX-301...
BioCentury | Oct 6, 2014
Clinical News

CDX-301: Pilot trial started

...Celldex began an open-label, U.S. pilot trial to evaluate CDX-301 for 5 or 7 days alone...
...trial is enrolling recipients with hematologic malignancies. Celldex has exclusive rights to develop and commercialize CDX-301...
...markets Mozobil. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-301...
BioCentury | Nov 12, 2012
Clinical News

CDX-301: Phase I data

...18 healthy volunteers in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily subcutaneous CDX-301...
...was 1 dose-limiting toxicity (DLT) of community-acquired pneumonia (CAP) at the 75 µg/kg dose of CDX-301...
...3 subjects across multiple dose levels. Patients received 1, 3, 10, 25 or 75 µg/kg CDX-301...
BioCentury | Jan 23, 2012
Clinical News

CDX-301: Phase I started

...began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1-75 mg/kg IV or subcutaneous CDX-301...
...5-10 days in about 30 healthy volunteers. Celldex has exclusive rights to develop and commercialize CDX-301...
...13, 2009). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-301...
Items per page:
1 - 4 of 4